SCHEMBL6776476

SCHEMBL6776476

COC(=O)C(Cc1ccccc1)NC(=O)CNC(=O)c1cc(N)ccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 3/20 0.51
ATM Q13315 2/20 0.50
GPR139 Q6DWJ6 1/20 0.50
NOS3 P29474 1/20 0.48
NOS1 P29475 1/20 0.48
POLB P06746 1/20 0.48
PYGL P06737 1/20 0.47
ALDH1A1 P00352 3/20 0.47
LMNA P02545 1/20 0.47
GLA P06280 1/20 0.47
THRB P10828 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
TACR3 P29371 1/20 0.46
KDM4E B2RXH2 1/20 0.46
PKM P14618 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3975891 0.81 HDAC1 (0.53) NOS2PYGLALDH1A1TACR3KDM4E
SCHEMBL3975886 0.81 HDAC1 (0.53) NOS2PYGLALDH1A1TACR3KDM4E
SCHEMBL28914294 0.78 ATM (0.60) ATMPOLBALDH1A1LMNAGLA
SCHEMBL28914295 0.78 ATM (0.60) ATMPOLBALDH1A1LMNAGLA
SCHEMBL6776471 0.78 GPR139 (0.54) ATMGPR139TACR3MEN1KMT2A
SCHEMBL22370283 0.77 PSMB5 (0.50) NOS2PYGLALDH1A1TACR3KDM4E
SCHEMBL22370286 0.77 PSMB5 (0.50) NOS2PYGLALDH1A1TACR3KDM4E
SCHEMBL6773596 0.77 GPR139 (0.51) GPR139LMNAKDM4EKMT2A
SCHEMBL28611896 0.77 NOS2 (0.61) NOS2ATMNOS3NOS1POLB
SCHEMBL16005297 0.77 ATM (0.62) ATMPOLBALDH1A1LMNAGLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed